Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Satsuma Pharmaceuticals, Inc is a biotechnology business based in the US. Satsuma Pharmaceuticals shares (STSA) are listed on the NASDAQ and all prices are listed in US Dollars. Satsuma Pharmaceuticals employs 17 staff and has a market cap (total outstanding shares value) of USD$87.5 million.
|Latest market close||USD$4.85|
|52-week range||USD$3.5 - USD$36.105|
|50-day moving average||USD$4.2149|
|200-day moving average||USD$15.9549|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-11.813|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-06)||N/A|
|1 month (2020-12-14)||0.21%|
|3 months (2020-10-13)||18.00%|
|6 months (2020-07-13)||-80.23%|
|1 year (2020-01-13)||-73.03%|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing Satsuma Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Satsuma Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Satsuma Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Satsuma Pharmaceuticals shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-26.8%|
|Return on equity TTM||-45.64%|
|Market capitalisation||USD$87.5 million|
TTM: trailing 12 months
There are currently 713,020 Satsuma Pharmaceuticals shares held short by investors – that's known as Satsuma Pharmaceuticals's "short interest". This figure is 12.2% down from 812,554 last month.
There are a few different ways that this level of interest in shorting Satsuma Pharmaceuticals shares can be evaluated.
Satsuma Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Satsuma Pharmaceuticals shares currently shorted divided by the average quantity of Satsuma Pharmaceuticals shares traded daily (recently around 200286.51685393). Satsuma Pharmaceuticals's SIR currently stands at 3.56. In other words for every 100,000 Satsuma Pharmaceuticals shares traded daily on the market, roughly 3560 shares are currently held short.
However Satsuma Pharmaceuticals's short interest can also be evaluated against the total number of Satsuma Pharmaceuticals shares, or, against the total number of tradable Satsuma Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Satsuma Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Satsuma Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1812% of the tradable shares (for every 100,000 tradable Satsuma Pharmaceuticals shares, roughly 181 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Satsuma Pharmaceuticals.
Find out more about how you can short Satsuma Pharmaceuticals stock.
We're not expecting Satsuma Pharmaceuticals to pay a dividend over the next 12 months.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.